公开(公告)号：US11633353B2

公开(公告)日：2023-04-25

申请号：US16619176

申请日：2018-06-05

申请人： DIZLIN PHARMACEUTICALS AB

发明人： Elias Eriksson ,  Nil Dizdar Segrell ,  Mats Ehrnebo ,  Leif Bring

IPC分类号： A61K9/08 ,  A61K31/198 ,  A61K47/12 ,  A61K9/00 ,  A61K47/18 ,  A61K45/06 ,  A61P25/16 ,  A61K47/02 ,  A61K47/26 ,  A61P25/00 ,  A61K47/40

摘要： The invention provides an aqueous pharmaceutical solution for use in the treatment of diseases of the central nervous system (CNS), the solution comprising at least 5 mg/ml dissolved levodopa, and having a pH in the range of 3.0 to 8.5. Said solution is provided by mixing a) an aqueous stock solution comprising levodopa, said stock solution having a pH of less than 2.8 at 25° C. and b) an aqueous buffering solution, for increasing the pH of said stock solution, said buffering solution having a pH of at least 4.0 at 25° C. The aqueous pharmaceutical solution is administered to a subject suffering from a disease of the central nervous system (CNS) shortly after mixing of the aqueous stock solution and the aqueous buffering solution. Furthermore, the invention provides a kit for administration of aqueous pharmaceutical solutions to subjects suffering from diseases of the central nervous system (CNS).

公开(公告)号：US12048764B2

公开(公告)日：2024-07-30

申请号：US18175599

申请日：2023-02-28

申请人： DIZLIN PHARMACEUTICALS AB

发明人： Elias Eriksson ,  Nil Dizdar Segrell ,  Mats Ehrnebo ,  Leif Bring

IPC分类号： A61K9/08 ,  A61K9/00 ,  A61K31/198 ,  A61K47/02 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26 ,  A61K47/40 ,  A61P25/00 ,  A61P25/16 ,  A61K45/06

CPC分类号： A61K9/08 ,  A61K9/0019 ,  A61K31/198 ,  A61K47/02 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26 ,  A61K47/40 ,  A61P25/00 ,  A61P25/16 ,  A61K45/06

摘要： An aqueous pharmaceutical solution for use in the treatment of diseases of the central nervous system (CNS), comprises at least 5 mg/ml dissolved levodopa and has a pH in the range of 3.0 to 8.5. The solution is provided by mixing a) an aqueous stock solution comprising levodopa and having a pH of less than 2.8 at 25° C., and b) an aqueous buffering solution having a pH of at least 4.0 at 25° C. for increasing the pH of the stock solution. The aqueous pharmaceutical solution is administered to a subject suffering from a disease of the CNS shortly after mixing of the aqueous stock solution and the aqueous buffering solution. A kit for administration of the aqueous pharmaceutical solution includes a bag comprising two parts and a removable or perforable barrier between the two parts.